KIMS promoters inject ₹600 cr via warrants to retire debt, fund expansion
The preferential issue of 77 lakh warrants at ₹779 each amounts to 15% of revenue. Proceeds will reduce debt and bankroll greenfield hospitals as Q4 profit slumped 69%.
— 1 earlier story on Krishna Institute of Medical Sciences Ltd →What's new
- Board approved 77,02,182 warrants to promoters at ₹779 each, raising ₹600 cr.
- Proceeds earmarked for debt reduction and greenfield hospital projects.
- Issue size equals ~15% of annual revenue, crossing materiality threshold.
Why this matters
Promoters are putting ₹600 cr of their own money into a company where net profit just dropped 69% year-on-year. That is a strong conviction signal, but the 11% dilution over 18 months creates near-term uncertainty, especially with a ₹1,500 cr QIP still on the table.
What we're watching
- Shareholder approval at the EGM on July 9, 2026.
- Whether the QIP plan (₹1,500 cr) is shelved or pursued concurrently.
- Impact on debt/equity (currently 0.89) after debt repayment.
The full read
The board approved a preferential issue of 77,02,182 warrants to promoter entities (Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP) at ₹779 per warrant, raising ₹600 crore. This amount equals 15% of annual revenue of ₹3,905 crore, crossing the materiality threshold for a mid-cap company. Proceeds will retire debt (debt/equity stands at 0.89) and fund greenfield hospitals. The news follows a tough Q4 FY26 where net profit plunged 69% to ₹31 crore on expansion costs, and the company had previously flagged a ₹1,500 crore QIP plan. Promoters putting their own money at this stage is a strong vote of confidence, but the 11% dilution over 18 months and the unresolved QIP overhang weigh on sentiment. The ₹600 crore infusion gives KIMS firepower to reduce debt and grow, but execution will determine whether this move lifts or burdens the stock.
Questions answered
- Why did KIMS choose a preferential warrant issue over a QIP?
- The warrant route allows promoters to infuse capital at a fixed price while retaining conversion flexibility for 18 months. It also signals promoter confidence, unlike a pure QIP which dilutes all shareholders. The company had previously announced a ₹1,500 cr QIP, which may now be reconsidered.
- What will the ₹600 cr be used for?
- The filing says proceeds will retire existing debt and fund greenfield hospital projects across multiple states. KIMS had a debt/equity of 0.89 as of the latest quarter, and Q4 FY26 net profit fell 69% to ₹31 cr, partly due to expansion costs.
- How much dilution do the warrants represent?
- The 77 lakh warrants convert into equity shares over 18 months. Based on KIMS's current share count (roughly 7.2 cr shares), full conversion would dilute existing shareholders by about 11%. The exercise price of ₹779 is at a modest premium to the current trading price.
- What does this mean for minority shareholders?
- The infusion reduces leverage and funds growth, but the dilution and the overhang of a potential QIP could pressure near-term valuation. The strong promoter backing is positive, but investors will watch execution of greenfield projects given the profit drag from existing expansion.
- Has KIMS done this before?
- In May 2026, KIMS announced plans for a ₹1,500 cr QIP to fund expansion. The current preferential issue to promoters is a new, material development that differs in structure and amount, reflecting a direct promoter commitment rather than a broad institutional raise.
Krishna Institute of Medical Sciences Ltd
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on KIMS →- 13 Jun 2026 · 1:02 PM IST KIMS promoters inject ₹600 cr via warrants to retire debt, fund expansion
- 22d ago KIMS plans ₹1,500 cr QIP as profit slides 69% on expansion drag